Sort   by:  
 Page size 
MetabolomicsFuzheng Jiedu Xiaoji Formula Enhances Anti-PD-1 Therapy for Hepatocellular Carcinoma by Inhibiting Regulatory T Cell Lipotoxicity

Background: The objective response rate of anti-programmed death receptor 1 (PD-1) immunotherapy in hepatocellular carcinoma (HCC) remains limited. The tumor immunosuppressive microenvironment mediated by regulatory T cells (Tregs) is a key bottleneck. The traditional Chinese medicine (TCM) compo...

2025-12-05 | MTBLS13458 | MetaboLights
MetabolomicsFecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining ...

2025-02-27 | MTBLS711 | MetaboLights
MetabolomicsCeramide Disrupts TM9SF2-PGK1 Axis to Redirect PD-L1 Trafficking and Enhance Antitumor Immunity

The PD-1/PD-L1 axis represents a cornerstone of cancer immunotherapy, yet the dynamic shuttling of PD-L1 between endosomal recycling and lysosomal degradation routes limits durable responses. Using a CRISPR screen targeting glycosphingolipid metabolism, we identify TM9SF2 as a key regulator of PD...

2026-02-05 | MTBLS13838 | MetaboLights
MetabolomicsMethionine Intervention Induces PD-L1 Expression to Enhance the Immune Checkpoint Therapy Response in MTAP-deleted Osteosarcoma
Osteosarcoma (OS), a malignant bone tumor with limited treatment options, exhibits low sensitivity to immune checkpoint therapy (ICT). Through genomics and transcriptomics analyses, we have identified a subgroup of OS with methylthioadenosine phosphorylase (MTAP) deletion, which contributes to ICT r...
2026-06-09 | MTBLS11985 | MetaboLights
MetabolomicsChanges in L-phenylalanine concentration reflect and predict response to anti-PD-1 treatment combined with chemotherapy in patients with non-small cell lung cancer
Chemotherapy combined with checkpoint blockade antibodies targeting programmed cell death protein (PD-1) has achieved remarkable success in non-small cell lung cancer (NSCLC). However, few patients benefit from long-term treatment. Therefore, biomarkers capable of guiding the optimal therapeutic sel...
2025-06-16 | MTBLS11232 | MetaboLights
MetabolomicsCaffeine Enhances Antitumor T-cell Activity via COL12A1/IDO1/Kyn axis and Sensitivity to Anti-PD-1 Immunotherapy in Colorectal Cancer
Metabolomic sequencing on supernatants from caffeine-treated and untreated tumor cells to identify which metabolites are involved in activating CD8+ T cells
2025-05-06 | MTBLS11623 | MetaboLights
TranscriptomicsComparison of gene expression profiles of Jurkat cells with or without PD-1 ligation
CD8+ T cells in chronic viral infections like HIV develop functional defects such as loss of IL-2 secretion and decreased proliferative potential that are collectively termed exhaustion1. Exhausted T cells express increased levels of multiple inhibitory receptors, such as Programmed Death 1 (PD-1)...
ORGANISM(S): Homo sapiens 
2010-10-03 | E-GEOD-24026 | biostudies-arrayexpress
GenomicsStreptomyces sp. PD-S100-1 isolate:PD-S100-1
Streptomyces sp. PD-S100-1 isolate:PD-S100-1 Genome sequencing
PRJNA1212226 | ENA
GenomicsStreptomyces noursei PD-1
Streptomyces noursei PD-1 Genome sequencing and assembly
PRJNA217850 | ENA
TranscriptomicsComparison of gene expression profiles of HIV-specific CD8 T cells from controllers and progressors and Jurkat cells with or without PD-1 ligation
This SuperSeries is composed of the following subset Series: GSE24026: Comparison of gene expression profiles of Jurkat cells with or without PD-1 ligation GSE24081: Comparison of gene expression profiles of HIV-specific CD8 T cells from controllers and progressors Refer to individual Series
ORGANISM(S): Homo sapiens 
2010-10-03 | E-GEOD-24082 | biostudies-arrayexpress
Sort   by:  
 Page size